



## Research Brief

## Impact of stress hyperglycemia on myocardial salvage in patients with ST-Elevation myocardial infarction: Cardiac magnetic resonance study

Taghreed Sayed Meshref<sup>a,\*</sup>, Refaat Fathi Abd El- Aal<sup>a</sup>, Mahmoud Aly Ashry<sup>a</sup>, Hisham Mostafa Imam<sup>b</sup>, Ahmad B. Elden<sup>a</sup>

<sup>a</sup> Cardiology and Critical Care Unit, Internal Medicine Department, Faculty of Medicine, Assiut University, Assiut, Egypt

<sup>b</sup> Radiology Department, Faculty of Medicine, Assiut University, Assiut, Egypt

## ARTICLE INFO

## Article history:

Received 14 March 2020

Accepted 9 August 2020

Available online 19 August 2020

## Keywords:

Cardiac magnetic resonance

Myocardial salvage

Stress hyperglycemia

## ABSTRACT

Cardiovascular complications in ST-segment–elevation myocardial infarction survivors remain substantial despite advances in the management of STEMI. We aimed to determine effect of AH on the area at risk (AAR), final infarct size (FIS), and salvage index (SI) in STEMI patients using cardiac magnetic resonance (CMR). 43 successfully reperfused STEMI patients were recruited. CMR was utilized to estimate AAR and FIS, SI was calculated:  $SI = AAR - FIS/AAR$ . AH showed significant positive correlations to FIS ( $r$ -value = 0.538,  $P = < 0.001$ ), and AAR ( $r$ -value = 0.435,  $P = 0.002$ ), and a negative correlation with SI ( $r$ -value =  $-0.378$ ,  $P = 0.006$ ).

© 2020 Cardiological Society of India. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

## 1. Introduction

Accounting for more than fifteen million deaths in 2016, cardiovascular diseases are the leading causes of death worldwide.<sup>1</sup> In the last decade, the mortality rates after ST-elevation myocardial infarction (STEMI) showed an obvious decline but, in low and middle-income countries, it is still relatively high.<sup>1</sup> Admission hyperglycemia (AH) has been determined to inversely affect short and long-term prognosis in patients with STEMI regardless of their diabetic state.<sup>2</sup> That can be partially explained by larger final infarct size (FIS) in AH patients compared with euglycemic patients.<sup>3</sup> Single-photon emission computed tomography (SPECT) is the traditional imaging tool utilized to measure FIS and area at risk (AAR) but, it has a limited spatial resolution and, carry the risk of radiation.<sup>4</sup> Cardiac magnetic resonance (CMR) is a relatively new cardiac imaging modality with many advantages, it can detect changes in cardiac contractile function and membrane integrity. Furthermore, CMR has a high spatial and temporal resolution which facilitates accurate assessment of cardiovascular structures. By the addition of late gadolinium enhancement (LGE) with CMR, transmural extension and scar tissues can be estimated.<sup>5</sup> A few data

about the sequelae of AH on AAR and salvage index (SI) after acute STEMI patients are available.

## 2. Methods

Forty-three patients (21 with stress hyperglycemia and 22 without) were selected from the Critical care Unit, Internal Medicine Department from April 2017, and May 2019. They presented with first STEMI and underwent successful reperfusion by primary percutaneous coronary intervention (PCI). Patients  $\geq 85$  years old, with life-limiting non-cardiac disease, prior STEMI, left bundle branch block (LBBB), with any of the standard contraindications to magnetic resonance imaging (MRI), an estimated glomerular filtration rate  $< 30$  mL/min/1.73 m<sup>2</sup>, who were hemodynamically unstable, or who are clinically unfit to be transferred to CMR laboratory were excluded. Acute STEMI is defined according to the European Society of Cardiology/ACCF/AHA.<sup>6</sup>

AH was defined as the presence of random plasma glucose  $> 140$  mg/dL in non-diabetic patients within 2 h of admission.<sup>7</sup> In diabetic patients, 250 mg/dL is considered the cut-off level for AH.<sup>8</sup>

Demographic data and clinical history were recorded with electrocardiogram (ECG) data. Venous blood samples were taken to perform biochemical investigations.

CMR was performed 4–6 days after acute STEMI with a 1.5-Tesla scanner (Philips, Achieva). Short-axis slices (thickness of 5 mm with a slices gap of 10 mm) were defined from the base to the apex of the

\* Corresponding author. Internal Medicine Department, Assiut University Hospitals, Faculty of Medicine, Assiut University, Assiut, 71511, Egypt.

E-mail address: [toti\\_20001000@hotmail.com](mailto:toti_20001000@hotmail.com) (T.S. Meshref).

heart.<sup>9</sup> Imaging of the heart at the end-systolic and end-diastolic times to estimate left ventricular end-systolic volume (LVESV) and left ventricular end-diastolic volume (LVEDV) respectively. A dark-blood T2-weighted short-tau-inversion-recovery turbo-spin echo sequence (STIR) was applied to determine AAR (with edema) and a segmented inversion-recovery steady-state free precession sequence (PSIR) was used for late enhancement imaging 10 min after intravenous injection of 0.15 mmol/kg of gadolinium diethylenetriaminepentaacetic acid (Gd-DTPA) (Magnevist; Bayer Schering, Berlin, Germany). CMR studies were analyzed then offline (Philips Medical Systems, Nederland B.V). Also, the classic wall motion score index (WMSI), the new segmental 65–40–15 EF score, and the EF calculated from WMSI were all calculated.<sup>10</sup>

Left ventricular endo- and epicardial borders had been delineated, then reference normal area was drawn. AAR was defined as the percentage of LV volume delineated by the hyper-intense zone on T2-STIR images with signal intensity was >2 standard deviations above the mean signal obtained in the non-infarcted myocardium and was expressed as a percentage of normal myocardium. FIS was measured similarly to AAR but on PSIR sequences. SI was calculated according to the formula: SI = (area at risk - infarct size)/area at risk.

The continuous variables were presented as means ± standard deviation (SD) and categorical variables were expressed as percentages.

### 3. Results

The data showed that male is the predominate gender. Clinical and echocardiographic data are illustrated in (Table 1).

AH group, had significantly larger FIS and smaller SI than the euglycemic group (Table 2). There was a positive correlation between glucose level at admission and FIS ( $r$  value = 0.538) and AAR ( $r$  value = 0.435) and negative correlation with SI ( $r$  value = -0.378).

Multivariate linear regression analysis showed that male sex, smoking, APG, anterior infarction, and classic WMSI estimated by CMR might be independent predictors of SI (Table 3).

### 4. Discussion

The main finding of our study is that both CMR detected AAR and FIS in acute STEMI patients were positively correlated with admission plasma glucose while SI negatively correlated with it.

Low-income nations have special demographic and social characteristics which in turn, increase the possibility of the stress-induced conditions and its health-associated problems. Previous studies confirmed that elevated admission glucose level is a strong predictor of short-term adverse outcomes in patients with AMI but, no previous studies in our country regarding the impact of AH on AAR, FIS, or SI which is the major concept of our research.<sup>11</sup>

An Indian study had addressed the association of AHG and increased myocardial damage evidenced by cardiac biomarkers and echocardiographic derived data but without using CMR.<sup>12</sup> In that study increased admission plasma glucose was associated with lower LVEF, higher WMSI, higher CKMB in STEMI patients, all in line with our results except for LVEF which had an insignificant association with APG in our studied population.<sup>12</sup>

APG was found to positively correlate with AAR in very few studies.<sup>13</sup> This could be explained by the augmented inflammatory

**Table 1**  
Patients clinical and echocardiographic characteristics.

	Euglycemic $n = 22$	Admission hyperglycemia $n = 21$	$p$ -value
Age/years (mean ± SD)	56.49 ± 11.4	58.95 ± 11.3	0.487 <sup>a</sup>
Sex (males%)	19 (86.4%)	17 (81%)	0.473 <sup>b</sup>
Hypertension $n$ (%)	12 (54.5%)	9 (42.9%)	0.443 <sup>b</sup>
Diabetes $n$ (%)	3 (13.6%)	6 (28.6%)	0.229 <sup>b</sup>
Smoking $n$ (%)	15 (68.2%)	11 (52.4%)	0.289 <sup>b</sup>
Chest Pain Duration/hours (mean ± SD)	6.36 ± 3.2	9.81 ± 5.2	<b>0.019<sup>c</sup></b>
BMI (kg/m <sup>2</sup> )	26.64 ± 4.8	25.52 ± 4.7	0.448 <sup>a</sup>
Heart Rate (beat/min)	84.09 ± 14.0	92.05 ± 11.2	0.050 <sup>a</sup>
SBP (mm/Hg)	118.46 ± 21.7	122.38 ± 23.2	0.587 <sup>a</sup>
DBP (mm/Hg)	75.91 ± 11.2	77.14 ± 15.1	0.767 <sup>a</sup>
Killip Score			
Class I	19 (86.4%)	18 (85.7%)	0.951 <sup>a</sup>
Class II	3 (13.6%)	3 (14.3%)	
Anterior $n$ (%)	7 (31.8%)	13 (61.9%)	<b>0.048<sup>b</sup></b>
Admission Sum of STE/mm (mean ± SD)	11.09 ± 9.8	18.14 ± 7.9	<b>0.002<sup>c</sup></b>
Admission Max. STE/mm (mean ± SD)	3.59 ± 2.3	5.10 ± 1.8	<b>0.003<sup>c</sup></b>
Resolution of STE $n$ (%)			
≥50–70	10 (45.5%)	8 (38.1%)	0.625 <sup>b</sup>
≥70	12 (54.5%)	13 (61.9%)	
LDL (mg/dl) (mean ± SD)	108.41 ± 35.5	106.38 ± 28.6	0.874 <sup>c</sup>
S. Creatinine (mg/dL) (mean ± SD)	0.95 ± 0.2	1.01 ± 0.2	0.259 <sup>c</sup>
Initial CK-MB (ng/mL) (mean ± SD)	57.14 ± 36.9	64.76 ± 42.5	0.381 <sup>c</sup>
Peak CK-MB (ng/ml) (mean ± SD)	245.23 ± 184.3	306.38 ± 174.2	0.162 <sup>c</sup>
HBA1c	5.11 ± 0.9	5.50 ± 0.9	0.087 <sup>c</sup>
Classic WMSI (mean ± SD)	1.38 ± 0.3	1.52 ± 0.2	<b>0.042<sup>c</sup></b>
LVESV (mL) (mean ± SD)	41.71 ± 13.7	40.96 ± 12.7	0.356 <sup>c</sup>
LVEDV (mL) (mean ± SD)	81.95 ± 18.5	75.60 ± 15.9	0.789 <sup>c</sup>
EF % (mean ± SD)	54.05 ± 11.5	50.81 ± 12.0	0.462 <sup>c</sup>

**BMI**, body mass index; **CK**, creatinine kinase; **DBP**, diastolic blood pressure; **EF**, ejection fraction; **HBA1c**, glycated hemoglobin; **LDL**, low density lipoprotein; **LVEDV**, left ventricular end diastolic volume; **LVESV**, left ventricular end systolic volume; **Max of STE**, maximum ST-segment elevation; **SBP**, systolic blood pressure; **SD**, standard deviation; **Sum of STE**, summation of ST-segment elevations; **WMSI**, wall motion score index.

$p$ -value <0.05 is significant.

<sup>a</sup> Independent  $t$ -test was used to compare the mean difference between groups.

<sup>b</sup> Chi-square test was used to compare the proportion differences.

<sup>c</sup> Mann-Whitney  $U$  test was used to compare the median difference between groups.

**Table 2**  
Cardiovascular magnetic resonance imaging findings.

	Euglycemic n = 22	Admission hyperglycemia n = 21	p-value
LVESV (mL)	75.42 ± 21.2	81.39 ± 26.9	0.360 <sup>a</sup>
LVEDV (mL)	136.71 ± 22.2	140.89 ± 24.1	0.679 <sup>a</sup>
Classic WMSI	1.39 ± 0.3	1.56 ± 0.2	<b>0.021<sup>a</sup></b>
EF calculated from WMSI (%)	55.41 ± 6.7	51.98 ± 5.9	0.075 <sup>b</sup>
New segmental EF 65–40–15 score (%)	55.26 ± 6.1	49.36 ± 7.1	<b>0.006<sup>b</sup></b>
EF %	51.09 ± 12.8	49.45 ± 13.1	0.590 <sup>a</sup>
FIS %	19.73 ± 9.5	28.05 ± 13.1	<b>0.022<sup>a</sup></b>
AAR %	31.59 ± 13.4	39.62 ± 16.6	0.135 <sup>a</sup>
SI	0.38 ± 0.1	0.34 ± 0.3	<b>0.031<sup>a</sup></b>
MVO. n (%)	6 (27.3%)	13 (61.9%)	<b>0.022<sup>b</sup></b>

**AAR**, area at risk; **EF**, ejection fraction; **FIS**, final infarct size; **LVEDV**, left ventricular end diastolic volume; **LVESV**, left ventricular systolic volume; **MVO**, microvascular obstruction; **SD**, standard deviation; **SI**, salvage index; **WMSI**, wall motion score index.  
p-value <0.05 is significant.

Values are given as mean ± SD.

<sup>a</sup> Mann-Whitney U test was used to compare the median difference between groups.

<sup>b</sup> Independent t-test was used to compare the mean difference between groups.

**Table 3**  
Multivariable Linear Regression, predictors of myocardial salvage.

	Estimate	SE	t-stat.	p-value
Age (years)	0.005 (−0.001–0.011)	0.01	1.60	0.117
Sex (Male)	−0.215 (−0.384–0.045)	0.08	−2.65	<b>0.014</b>
Heart Rate (beat/minute)	−0.001 (−0.006–0.004)	0.03	−0.46	0.649
SBP (mmHg)	−0.001 (−0.004–0.002)	0.02	−0.47	0.642
DBP (mmHg)	−0.001 (−0.006–0.004)	0.03	−0.41	0.810
Chest Pain Duration/hours	−0.002 (−0.017–0.013)	0.01	−0.27	0.785
DM	−0.097 (−0.259–0.066)	0.08	−1.20	0.237
Hypertension	−0.024 (−0.159–0.110)	0.07	−0.36	0.720
Smoker	−0.156 (−0.284–0.027)	0.06	−2.45	<b>0.019</b>
LDL (mg/dL)	0.001 (−0.001–0.003)	0.01	1.06	0.294
APG (mg/dL)	−0.081 (−0.287–0.001)	0.02	−3.16	<b>0.021</b>
Peak CK-MB (ng/mL)	−0.001 (−0.015–0.012)	0.16	−0.54	0.427
CMR WMSI	0.120 (0.042–0.285)	0.13	4.95	<b>0.036</b>
CMR LVESV (mL)	0.001 (−0.003–0.003)	0.01	0.99	0.327
CMR LVEDV (mL)	0.001 (−0.001–0.004)	0.01	0.07	0.946
Infarction Site (Anterior)	−0.116 (−0.259–0.031)	0.04	−3.98	<b>0.033</b>
MVO	−0.024 (−0.159–0.112)	0.06	−0.35	0.726

**APG**, admission plasma glucose; **CK**, creatinine kinase; **CMR**, cardiac magnetic resonance; **DBP**, diastolic blood pressure; **DM**, diabetes mellitus; **LDL**, low density lipoprotein; **LVEDV**, left ventricular end diastolic volume; **LVESV**, left ventricular end systolic volume; **MVO**, microvascular obstruction; **SBP**, systolic blood pressure; **WMSI**, wall motion score index.  
p-value <0.05 is significant.

response during STEMI induced by hyperglycemia which in turn increases the microvascular permeability and tissue edema.<sup>14</sup>

Ekmekci et al was the first to study SI in STEMI patients and have demonstrated that admission hyperglycemia independently predicted the extent of SI in non-diabetic patients.<sup>15</sup> On the contrary Lønborg et al found that admission hyperglycemia was associated with larger FIS and AAR without affecting SI.<sup>13</sup> In ours, admission hyperglycemia inversely affected the SI. The rapid rise in plasma glucose levels acutely exaggerates inflammation by increasing the levels of circulating cytokines, which increase intracellular Ca<sup>+</sup> overload and subsequent progression into irreversible cell death which in turn increases FIS and reduces salvageable myocardium.<sup>15</sup>

To determine the independent predictors of SI, the current study showed that smoking and male gender were independent predictors of impaired SI. Male predominance in our study population and high smoking percent can explain these results. In agreement with a previous study, WMSI was an independent predictor of salvageable myocardium.<sup>11</sup>

In another study, the anterior location was an independent predictor of myocardial salvage,<sup>3</sup> agreeing with our results, this is mostly explained by larger AAR in anterior infarctions.

APG was the strong independent predictor of SI detected in our study in concordance with a previous study which addressed the benefits of glycemic control on admission.<sup>15</sup>

The majority of the mentioned studies entailed AHG in non-diabetics only, and if diabetics were included, they utilized lower cut-off values for diagnoses of AHG which thus may include many falsely diagnosed candidates.

The current study is limited by the absence of follow-up data which could better determine the actual scar size. Moreover, interpretation should be applied to low- and moderate-risk STEMI patients as high-risk STEMI patients were excluded.

### Key message

Admission hyperglycemia is an independent predictor of CMR assessed AAR, FIS, and SI in successfully reperfused STEMI. These results favor the importance of strict glucose control at the acute phase of STEMI.

### Declaration of competing interest

All authors have none to declare.

### References

1. Organization WH. *Fact Sheet: The Top 10 Causes of Death*. Geneva, Switzerland: World Health Organization; 2017.
2. Cinar H, Akkan Avci MG, Avci BS, et al. Does stress hyperglycemia affect mortality? Acute myocardial infarction—case control study. *Arch Med Sci Atheros Dis*. 2019;4, e201.
3. Eitel I, Hintze S, Waha Sd, et al. Prognostic impact of hyperglycemia in nondiabetic and diabetic patients with ST-elevation myocardial infarction: insights from contrast-enhanced magnetic resonance imaging. *Circ Cardiovasc Imaging*. 2012;5(6):708–718.
4. Aziz EF, Javed F, Alviar CL, et al. Triple vessel coronary artery disease presenting as a markedly positive stress electrocardiographic test and a negative SPECT-TL scintigram: a case of balanced ischemia. *Heart Int*. 2011;6(2):2011. e22.
5. Miranda IFA. Viabilidad miocárdica Y los principales métodos para su detección. *CorSalud*. 2009;1(3):4.
6. Thygesen K, Alpert JS, Jaffe AS, et al. Fourth universal definition of myocardial infarction (2018). *J Am Coll Cardiol*. 2018;72(18):2231–2264.
7. Deedwania P, Kosiborod M, Barrett E, et al. Hyperglycemia and acute coronary syndrome A scientific statement from the American heart association diabetes committee of the council on nutrition, physical activity, and metabolism. *Anesthesiology*. 2008;109:14–24.
8. Rau C-S, Wu S-C, Chen Y-C, et al. Stress-induced hyperglycemia in diabetes: a cross-sectional analysis to explore the definition based on the trauma registry data. *Int J Environ Res Publ Health*. 2017;14(12):1527.

9. Cottin Y, Touzery C, Guy F, et al. MR imaging of the heart in patients after myocardial infarction: effect of increasing intersection gap on measurements of left ventricular volume, ejection fraction, and wall thickness. *Radiology*. 1999;213(2):513–520.
10. Lebeau R, Di ML, Amyot R, et al. A new tool for estimating left ventricular ejection fraction derived from wall motion score index. *Can J Cardiol*. 2003;19(4):397–404.
11. Khalfallah M, Abdelmageed R, Elgendy E, et al. Incidence, predictors and outcomes of stress hyperglycemia in patients with ST elevation myocardial infarction undergoing primary percutaneous coronary intervention. *Diabetes Vasc Dis Res*. 2019, 1479164119883983.
12. Ishihara M. Acute hyperglycemia in patients with acute myocardial infarction. *Circ J*. 2012;76(3):563–571.
13. Lønborg J, Vejstrup N, Kelbæk H, et al. Impact of acute hyperglycemia on myocardial infarct size, area at risk, and salvage in patients with STEMI and the association with exenatide treatment: results from a randomized study. *Diabetes*. 2014;63(7):2474–2485.
14. Marfella R, Siniscalchi M, Esposito K, et al. Effects of stress hyperglycemia on acute myocardial infarction: role of inflammatory immune process in functional cardiac outcome. *Diabetes Care*. 2003;26(11):3129–3135.
15. Ekmekci A, Cicek G, Uluganyan M, et al. Admission hyperglycemia predicts inhospital mortality and major adverse cardiac events after primary percutaneous coronary intervention in patients without diabetes mellitus. *Angiology*. 2014;65(2):154–159.